ArticleNeuropsychiatric disease and treatment2014
Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
Article in Neuropsychiatric disease and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.Alzheimer's research & therapy · 2020Pooled it
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Pooled it
- Cognitive Outcomes After Hip Fracture Surgery: The Association of Postoperative Delirium on Previously Cognitively Normal Older Adults.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Trial
- Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.Journal of pharmacokinetics and pharmacodynamics · 2023Trial
- Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease.BMC neuroscience · 2021Trial
- 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Trial
- The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?Clinical interventions in aging · 2019Trial
- Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Validity of the two different scoring methods of the Clinical Dementia Rating scale in staging and detection of cognitive impairment in the Peruvian population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Baseline facial emotion recognition is associated with clinical decline across the Alzheimer's disease spectrum: a multi-instrument longitudinal assessment study.Frontiers in aging neuroscience · 2026Article
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea) · 2026Article
- APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer's Disease: A mixed-effects disease progression model.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Development and Preliminary Validation of Standardized Regression-Based Change Scores as Measures of Transitional Cognitive Decline.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Article
- The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making.Clinical pharmacology and therapeutics · 2025Review
- Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer's patients: A double-blind placebo-controlled randomized clinical trial.IBRO neuroscience reports · 2024Article
- Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.CPT: pharmacometrics & systems pharmacology · 2023Observational
- Measurement of Prevalent Versus Incident Dementia Cases in Epidemiologic Studies.American journal of epidemiology · 2023Article
- Prediction of Cognitive Degeneration in Parkinson's Disease Patients Using a Machine Learning Method.Brain sciences · 2022Article
- Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe objective of this analysis was to develop a nonlinear disease progression model, using an expanded set of covariates that captures the longitudinal Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores. These were derived from the Alzheimer's Disease Neuroimaging Initiative ADNI-1 study, of 301 Alzheimer's disease and mild cognitive impairment patients who were followed for 2-3 years.
methodsThe model describes progression rate and baseline disease score as a function of covariates. The covariates that were tested fell into five groups: a) hippocampal volume; b) serum and cerebrospinal fluid (CSF) biomarkers; c) demographics and apolipoprotein Epsilon 4 (ApoE4) allele status; d) baseline cognitive tests; and e) disease state and comedications.
resultsCovariates associated with baseline disease severity were disease state, hippocampal volume, and comedication use. Disease progression rate was influenced by baseline CSF biomarkers, Trail-Making Test part A score, delayed logical memory test score, and current level of impairment as measured by CDR-SB. The rate of disease progression was dependent on disease severity, with intermediate scores around the inflection point score of 10 exhibiting high disease progression rate. The CDR-SB disease progression rate in a typical patient, with late mild cognitive impairment and mild Alzheimer's disease, was estimated to be approximately 0.5 and 1.4 points/year, respectively.
conclusionsIn conclusion, this model describes disease progression in terms of CDR-SB changes in patients and its dependency on novel covariates. The CSF biomarkers included in the model discriminate mild cognitive impairment subjects as progressors and nonprogressors. Therefore, the model may be utilized for optimizing study designs, through patient population enrichment and clinical trial simulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.